Extract

This is a phase III multi-centre study in three periods: the first period is a phosphate binder washout for 4 weeks, the second period is an open-label, randomised, parallel group, flexible dose, the third period is a placebo-controlled withdrawal comparing MCI-196 with placebo for 4 weeks.

Inclusion criteria

• chronic kidney disease ,Hyperphosphatemia

Country

• Australia
• Austria
• Czech Republic
• France
• Germany
• Hungary
• Italy
• Poland
• South Africa
• Spain
• United Kingdom

Links

• nct
• ictrp